Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q6IMI4

UPID:
ST6B1_HUMAN

ALTERNATIVE NAMES:
Thyroxine sulfotransferase

ALTERNATIVE UPACC:
Q6IMI4; B2RTS7

BACKGROUND:
The enzyme Sulfotransferase 6B1, alternatively named Thyroxine sulfotransferase, is integral to thyroxine metabolism. It employs 3'-phospho-5'-adenylyl sulfate (PAPS) to transfer sulfate groups to thyroxine, a critical step in controlling the hormone's function in the body. This sulfation process is essential for maintaining metabolic balance and supporting overall physiological health.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Sulfotransferase 6B1 offers a promising pathway to developing therapeutic interventions. Given its central role in managing thyroxine levels, targeting this enzyme could lead to innovative treatments for disorders stemming from thyroid hormone dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.